2017
Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older
Lodi S, Costagliola D, Sabin C, del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill MJ, Krentz H, Phillips AN, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2017, 76: 311-318. PMID: 28746165, PMCID: PMC5704899, DOI: 10.1097/qai.0000000000001498.Peer-Reviewed Original ResearchConceptsGeneral HIV populationImmediate initiationHIV populationCD4 countCells/US veteransAIDS mortalityAIDS-free individualsNon-AIDS mortalityUS Veteran cohortHIV-positive individualsHIV-CAUSAL CollaborationAntiretroviral therapyCause mortalityAntiretroviral treatmentMedian ageClinical guidelinesVeteran cohortHigh mortalityMortalityCD4Younger participantsRiskBaselineVeteransComparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, Collaboration H, Systems C. Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. The Lancet HIV 2017, 4: e251-e259. PMID: 28411091, PMCID: PMC5492888, DOI: 10.1016/s2352-3018(17)30043-7.Peer-Reviewed Original ResearchConceptsCD4 cell countHIV-positive individualsVirological failureHazard ratioCell countViral loadRisk ratioObservational studyTime-varying CD4 cell countHIV RNA viral loadAntiretroviral therapy regimenCombination antiretroviral therapyRNA viral loadAIDS Research NetworkMortality hazard ratioIntegrated Clinical SystemsHIV-CAUSAL CollaborationLong-term safetyCell count differencesAntiretroviral therapyCD4 countTherapy regimenProspective studyImmunological outcomesClinical guidelines
2015
Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
Cain L, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins J, Sterne J, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende M, Abgrall S, Costagliola D, Hernán M. Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries. Clinical Infectious Diseases 2015, 60: 1262-1268. PMID: 25567330, PMCID: PMC4447777, DOI: 10.1093/cid/ciu1167.Peer-Reviewed Original ResearchConceptsAtazanavir regimenVirologic failureProspective studyNucleoside reverse transcriptase inhibitor (NRTI) backboneFirst-line antiretroviral regimensReverse transcriptase inhibitor backboneAIDS-free individualsTreat hazard ratiosCD4 cell countCurrent clinical guidelinesHuman immunodeficiency virusRandomized clinical trialsAdjusted intentionAntiretroviral regimensAtazanavir groupBoosted atazanavirContaining RegimensVirologic outcomesCD4 countNRTI backboneHazard ratioClinical outcomesImmunodeficiency virusClinical guidelinesClinical trials
2014
Guideline-Concordant Management of Opioid Therapy Among Human Immunodeficiency Virus (HIV)-Infected and Uninfected Veterans
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Weisberg DF, Justice AC, Fiellin DA. Guideline-Concordant Management of Opioid Therapy Among Human Immunodeficiency Virus (HIV)-Infected and Uninfected Veterans. Journal Of Pain 2014, 15: 1130-1140. PMID: 25152300, PMCID: PMC4253900, DOI: 10.1016/j.jpain.2014.08.004.Peer-Reviewed Original ResearchConceptsCurrent substance use disorderGuideline-concordant careOpioid therapyUrine drug testsHuman immunodeficiency virusSubstance use disordersUninfected patientsImmunodeficiency virusUse disordersPatient/provider characteristicsPrimary care provider visitsVeterans Affairs/DepartmentGuideline-concordant managementDrug testsCare concordantGuideline concordanceUninfected veteransProvider visitsPatient characteristicsPatient groupPrimary careClinical guidelinesPain medicineProvider characteristicsPatients
2009
The Payoff Time
Braithwaite RS, Fiellin D, Justice AC. The Payoff Time. Medical Care 2009, 47: 610-617. PMID: 19433991, PMCID: PMC3077952, DOI: 10.1097/mlr.0b013e31819748d5.Peer-Reviewed Original ResearchConceptsCR screeningComorbid illnessesPatient 1Patient 3Colorectal cancer screening decisionsColorectal cancer screening guidelinesCancer screening guidelinesCongestive heart failureInflammatory bowel diseasePrimary care patientsCancer screening decisionsLife expectancyUnnecessary health careBowel diseaseCare patientsHeart failurePatient 2Screening guidelinesLung diseaseClinical guidelinesCurrent guidelinesTypical patientPractice guidelinesGeneral practiceHealth services
2007
A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care
Braithwaite RS, Concato J, Chang CC, Roberts MS, Justice AC. A Framework for Tailoring Clinical Guidelines to Comorbidity at the Point of Care. JAMA Internal Medicine 2007, 167: 2361-2365. PMID: 18039996, PMCID: PMC3460384, DOI: 10.1001/archinte.167.21.2361.Peer-Reviewed Original ResearchConceptsCongestive heart failureHuman immunodeficiency virusComorbidity-adjusted life expectancyColorectal cancer screeningColorectal cancerClinical guidelinesCancer screeningLife expectancyHeart failureComorbidity profilesImmunodeficiency virusPoint of careIndividual patientsPatientsIncremental benefitCancerComorbiditiesWomenMenGuidelinesExpectancyPayoff timeScreeningYearsCare